Maria Teresa Rosanova1, Guadalupe Perez2, Maria Martha Katsicas3, Ana Paula Arias2, Micela Picollo3, Marcela Palladino4, Claudia Gonzalez4, Natalia Veliz4, Ana Buchovsky5, Roberto Lede6, Rosa Bologna2. 1. Department of Infectious Diseases Hospital Juan P Garrahan Combate de los Pozos 1881, Argentina. Correspondence to: Dr Maria Teresa Rosanova, Chief of Clinics, Department of Infectious Diseases, Hospital Juan P Garrahan, Combate de los Pozos 1881 Buenos Aires, Argentina. maritesolcito@gmail.com. 2. Department of Infectious Diseases Hospital Juan P Garrahan Combate de los Pozos 1881, Argentina. 3. Department of Rheumatology, Hospital Juan P Garrahan Combate de los Pozos 1881, Argentina. 4. Department of Clinics, 75, Hospital Juan P Garrahan Combate de los Pozos 1881, Argentina. 5. Department of Serology, Hospital Juan P Garrahan Combate de los Pozos 1881, Argentina. 6. Department of Universidad Abierta Interamericana (UAI), Avenida San Juan 961, Buenos Aires, Argentina.
Abstract
OBJECTIVE: To evaluate the differential characteristics of SARS-COV-2 associated inflammatory multisystem syndrome (MIS-C) in children. METHODS: A retrospective cohort study was conducted. The definition of MIS- C was based on WHO criteria. Temporally related COVID-19 patients were included as controls. RESULTS: 25 patients with MIS-C and 75 controls were included. Multivariate multiple logistic regression model of variables that showed to be significant in univariate analysis revealed that age ≥2 years (OR 24.7; 95% CI 1.03 -592.4; P=0.048), lymphopenia (OR 9.03, 95%CI 2.05-39.7; P=0.004), and platelet count <150x109/L (OR 11.7; 95% CI 1.88-75.22; P=0.009) were significantly associated with MIS-C. Presence of underlying disease seemed to reduce the risk of MIS-C (OR 0.06; 95% CI 0.01-0.3). CONCLUSIONS: MIS-C was more common in patients older than 2 years and in those with lymphopenia or thrombocytopenia. Underlying disease appears to reduce the risk of MIS-C.
OBJECTIVE: To evaluate the differential characteristics of SARS-COV-2 associated inflammatory multisystem syndrome (MIS-C) in children. METHODS: A retrospective cohort study was conducted. The definition of MIS- C was based on WHO criteria. Temporally related COVID-19patients were included as controls. RESULTS: 25 patients with MIS-C and 75 controls were included. Multivariate multiple logistic regression model of variables that showed to be significant in univariate analysis revealed that age ≥2 years (OR 24.7; 95% CI 1.03 -592.4; P=0.048), lymphopenia (OR 9.03, 95%CI 2.05-39.7; P=0.004), and platelet count <150x109/L (OR 11.7; 95% CI 1.88-75.22; P=0.009) were significantly associated with MIS-C. Presence of underlying disease seemed to reduce the risk of MIS-C (OR 0.06; 95% CI 0.01-0.3). CONCLUSIONS:MIS-C was more common in patients older than 2 years and in those with lymphopenia or thrombocytopenia. Underlying disease appears to reduce the risk of MIS-C.
Authors: Leora R Feldstein; Erica B Rose; Steven M Horwitz; Jennifer P Collins; Margaret M Newhams; Mary Beth F Son; Jane W Newburger; Lawrence C Kleinman; Sabrina M Heidemann; Amarilis A Martin; Aalok R Singh; Simon Li; Keiko M Tarquinio; Preeti Jaggi; Matthew E Oster; Sheemon P Zackai; Jennifer Gillen; Adam J Ratner; Rowan F Walsh; Julie C Fitzgerald; Michael A Keenaghan; Hussam Alharash; Sule Doymaz; Katharine N Clouser; John S Giuliano; Anjali Gupta; Robert M Parker; Aline B Maddux; Vinod Havalad; Stacy Ramsingh; Hulya Bukulmez; Tamara T Bradford; Lincoln S Smith; Mark W Tenforde; Christopher L Carroll; Becky J Riggs; Shira J Gertz; Ariel Daube; Amanda Lansell; Alvaro Coronado Munoz; Charlotte V Hobbs; Kimberly L Marohn; Natasha B Halasa; Manish M Patel; Adrienne G Randolph Journal: N Engl J Med Date: 2020-06-29 Impact factor: 91.245
Authors: Moises Rodriguez-Gonzalez; Ana Castellano-Martinez; Helena Maria Cascales-Poyatos; Alvaro Antonio Perez-Reviriego Journal: World J Clin Cases Date: 2020-11-06 Impact factor: 1.337
Authors: Lauren A Henderson; Scott W Canna; Kevin G Friedman; Mark Gorelik; Sivia K Lapidus; Hamid Bassiri; Edward M Behrens; Anne Ferris; Kate F Kernan; Grant S Schulert; Philip Seo; Mary Beth F Son; Adriana H Tremoulet; Rae S M Yeung; Amy S Mudano; Amy S Turner; David R Karp; Jay J Mehta Journal: Arthritis Rheumatol Date: 2020-10-03 Impact factor: 15.483
Authors: Alberto García-Salido; Juan Carlos de Carlos Vicente; Sylvia Belda Hofheinz; Joan Balcells Ramírez; María Slöcker Barrio; Inés Leóz Gordillo; Alexandra Hernández Yuste; Carmina Guitart Pardellans; Maite Cuervas-Mons Tejedor; Beatriz Huidobro Labarga; José Luís Vázquez Martínez; Míriam Gutiérrez Jimeno; Ignacio Oulego-Erróz; Javier Trastoy Quintela; Carmen Medina Monzón; Laura Medina Ramos; María Soledad Holanda Peña; Javier Gil-Antón; Clara Sorribes Ortí; José Carlos Flores González; Rosa María Hernández Palomo; Inma Sánchez Ganfornina; Emilia Fernández Romero; María García-Besteiro; Jesús López-Herce Cid; Rafael González Cortés Journal: Crit Care Date: 2020-11-26 Impact factor: 9.097
Authors: Li Jiang; Kun Tang; Mike Levin; Omar Irfan; Shaun K Morris; Karen Wilson; Jonathan D Klein; Zulfiqar A Bhutta Journal: Lancet Infect Dis Date: 2020-08-17 Impact factor: 71.421